TrialArteriosclerosis, thrombosis, and vascular biology2009

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

John S Millar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.